The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute (OSUCCC - James) | Strategic Alliance Partners

September 14, 2020

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

September 14, 2020

Kami J. Maddocks, MD, discusses the role of tazemetostat in patients with EZH2-mutant follicular lymphoma.

September 11, 2020

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

September 10, 2020

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

September 10, 2020

Kami J. Maddocks, MD, discusses the utility of BTK inhibitors in B-cell malignancies, challenges that are still faced in the space, and areas primed for additional development.

September 09, 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

September 03, 2020

David O'Malley, MD, discusses the adverse effects associated with mirvetuximab soravtansine in ovarian cancer.

September 01, 2020

Kami J. Maddocks, MD, discusses emerging therapies in follicular lymphoma.

August 14, 2020

Jennifer Woyach, MD, discusses the role of small molecule inhibitors in chronic lymphocytic leukemia.

August 14, 2020

Kami J. Maddocks, MD, discusses the clinical implications of the approval of tafasitamab and lenalidomide in relapsed/refractory DLBCL, as well as remaining challenges that future research efforts should address.

August 11, 2020

Jennifer Woyach, MD, discusses ​the role of chemoimmunotherapy in chronic lymphocytic leukemia.

June 24, 2020

David O'Malley, MD, discusses the utility of mirvetuximab soravtansine in ovarian cancer.

June 11, 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

June 10, 2020

Ritu Salani, MD, discusses opportunities for precision medicine in cervical cancer.

May 28, 2020

Gregory A. Otterson, MD, discusses data examining immunotherapy alone versus in combination in non–small cell lung cancer.

May 27, 2020

Jonathan E. Brammer, MD, discusses data that have been reported with inotuzumab ozogamicin (Besponsa) in acute lymphoblastic leukemia (ALL).

May 27, 2020

Alice S. Mims, MD, discusses the Beat AML Master Trial in acute myeloid leukemia (AML).

May 19, 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

May 19, 2020

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

May 05, 2020

Ritu Salani, MD, discusses the evolving role of biomarker development and testing in cervical cancer.